Parkinson’s Disease

Technology Modalities

Aspen Neuroscience’s Sasineprocel Receives RMAT Designation in Parkinson’s Disease

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Aspen Neuroscience’s sasineprocel (ANPD001), an autologous induced-pluripotent-stem-cell-derived dopaminergic neuron precursor therapy for Parkinson’s disease. The July 30 announcement was recovered as part of…

admin
July 30, 2026

All categories, Therapeutic Indication

Novo – Parkinson’s Cell Therapy Transfer

Novo Nordisk has transferred a Parkinson’s disease cell therapy program to Cellular Intelligence, reflecting continued asset recycling and lifecycle extension within the advanced cell therapy ecosystem.

admin
May 11, 2026

Aspen Neuroscience’s Sasineprocel Receives RMAT Designation in Parkinson’s Disease

Novo – Parkinson’s Cell Therapy Transfer

Saturday Rounds